INTRODUCTION
============

The Epstein-Barr virus (EBV) is a *Herpesvirus* that infects, in a persistent way, more than 90% of the adult population worldwide, resulting in an asymptomatic outcome in the majority of individuals. However, EBV has been associated with several lymphoid disorders such as infectious mononucleosis, Burkitt's lymphoma, Hodgkin's disease, and post-transplant lymphoproliferative disease (PTLD), as well as some solid tumors such as nasopharyngeal and gastric carcinomas ([@b42]). The association of the EBV with gastric carcinomas was observed at the beginning of the 1990s. The first report was in a case of lymphoepithelial-like gastric carcinoma ([@b7]), subsequently, it was identified in common gastric carcinomas ([@b47]). Afterwards, many works demonstrated that EBV displays an important role in gastric carcinogenesis, most of them reporting the presence of the virus in almost all tumor cells and the monoclonality of the viral genome ([@b13], [@b20], [@b40]).

During the past two decades, several studies in many countries were carried out. Although the polymerase chain reaction (PCR) had been used in the first detection of EBV in gastric carcinoma ([@b7]), the majority of studies have used RNA in situ hybridization (ISH) due to the possibility of viral genome amplification from infected lymphocytes infiltrating the tumor, resulting in a false-positive. Still, there are few studies using and comparing both techniques for EBV detection ([@b13], [@b20], [@b47], [@b57]).

It has been demonstrated, using RNA in situ hybridization, that EBV can be found in approximately 10% of gastric carcinomas. However, there are some regional differences in the frequency of EBV-positive gastric carcinoma. Countries with higher values include Japan (19.3%), Germany (18%) and United States (12--16%) ([@b18], [@b22], [@b40], [@b47]). Two studies conducted in Brazil demonstrated intermediate values, 8% and 11.3% ([@b27], [@b33]).

In spite of the several papers regarding EBV frequency in gastric carcinomas, the association of EBV with some clinico-pathological aspects is still controversial. Only a few consensuses involving EBV-associated cases have been established including average age of about 59 years old and predominance in males and in poorly to moderately differentiated tumors. Moreover, as mentioned, few studies have correlated results between ISH and PCR techniques. Therefore, the aim of the present study was to determine the occurrence of EBV in gastric carcinomas by RNA in situ hybridization and PCR, comparing the results of the techniques and correlating them with clinico-pathological findings.

MATERIALS AND METHODS
=====================

Clinical Specimens
------------------

One hundred ninety-two cases of surgically resected gastric carcinomas were obtained from Ceará and São Paulo States, Brazil, including two hospitals in Ceará State, namely Hospital Universitário Walter Cantídeo, Universidade Federal do Ceará and Santa Casa de Misericórdia de Fortaleza, and two hospitals in São Paulo State, namely Hospital das Clínicas de Botucatu, Faculdade de Medicina, UNESP, Botucatu and Hospital Amaral Carvalho, Jaú. The present study was previously approved by the Ethics Committee of the Universidade Federal do Ceará under protocol 199/2004, and informed consent was obtained from all participants before gastrectomy, abiding by the Resolution 196/1996 of the National Council of Health -- Ministry of Health/Brazil. Clinico-pathological data were collected from the subjects using an administered questionnaire and/or from medical reports. Some clinico-pathological data could not be obtained from the São Paulo samples. Fresh clinical specimens, obtained during the gastrectomies, were immediately sent to the associated laboratories, under refrigeration, and stored in a freezer at --80°C. The percentage of tumor cells was determined and only specimens containing at least 70% tumor cells were submitted to DNA extraction. Therefore, 151 cases were used for PCR analyses. Out of 192 cases, 160 representative specimens of formalin-fixed tumor embedded in paraffin blocks were obtained from the pathology archives of the referred hospitals for ISH application. The specimens were sectioned (5 μm thickness) and placed on silane-treated glass slides. Moreover, each sample was reviewed by a pathologist of the team to confirm the diagnosis of gastric carcinoma, tumor differentiation and histological type based on Lauren's classification. The tumor stages were defined based on the TNM classification present in the medical reports, according to the American Joint Committee on Cancer ([@b4]). Both techniques were performed in 120 out of 192 cases.

RNA In Situ Hybridization
-------------------------

The presence of EBV was assessed utilizing a 30-bp biotinylated probe complementary to viral RNA EBER1 ([@b47]). The ISH technique was carried out according to the following steps: deparaffinization; rehydration; endogenous peroxidase blockade with 3% H~2~O~2~; enzymatic digestion with proteinase K (0.02 μg/μL) for 13 min; incubation with pre-hybridization solution (Denhardt's solution \[3.5X\], SSC \[4.5X\], EDTA \[0.0075 M\], SDS \[0.35%\], NaH~2~PO~4~ \[0.75 M\], dextran sulfate \[10%\]) for 60 min at 37°C; overnight incubation at 37°C with hybridization solution containing 0.3 ng/μL of the probe; slide washes with 2X SSC buffer; and signal amplification using anti-biotin antibody (clone BK-1/39, mouse, dilution 1:20; DakoCytomation^®^; Denmark) and biotinylated anti-immunoglobulin antibody (polyclonal, rabbit, dilution 1:100; DakoCytomation^®^; Denmark). The detection was performed using the streptavidin-biotin-peroxidase method (DakoCytomation^®^; CA, USA) and 3,3'-diaminobenzidine (DakoCytomation^®^; CA, USA) as chromogen. In each reaction, an EBV-positive nasopharyngeal carcinoma case was used as positive control while a negative control was obtained by omitting the probe. Nuclei with a brown or black staining were considered positive. To insure that we did not lose any EBV-positive case, with staining in tumor cells and/or lymphocytes, which could have a small amount of EBER1 due to RNA degradation during the histological procedures, thirty random cases were also performed with the GenPoint^®^ detection system (DakoCytomation^®^, Code K0620; CA, USA), following the manufacturer's instructions.

DNA Extraction
--------------

The DNA extraction method was adapted from Foster and Twell ([@b12]), which utilizes the detergent cetyl trimethyl ammonium bromide (CTAB). Briefly, fragments of about 0.5 g were macerated in tubes containing 6 mL of extraction buffer (2% CTAB; 1.4 M NaCl; 20 mM EDTA; 100 mM Tris-HCl, pH 8.0; 0.2% 2-mercaptoethanol), and the contents mixed overnight at room temperature. DNA purification was performed with chloroform-isoamyl alcohol (24:1), with precipitation using 100% isopropanol; the DNA-CTAB complex was dissociated with the addition of 1 M NaCl. DNA was then precipitated with 100% ethanol, washed with 70% ethanol, dried at 37ºC and dissolved in RNAse- and DNAse-free water. The quality of the DNA extracted was analyzed by electrophoresis in 1% agarose gels, which were stained with ethidium bromide and observed with a UV transilluminator, and the quantity was measured with a spectrophotometer.

### Polymerase Chain Reaction (PCR)

The EBV genome was detected by amplification of a fragment from the EBNA1 gene utilizing the following primers: sense 5'- GTC ATC ATC ATC CGG GTC -3' and antisense 5'- TTC GGG TTG GAA CCT CCT TG -3' ([@b53]). The expected size of the reaction products was 269 bp. The reaction mix was composed of 1X PCR buffer (20 mM Tris-HCl \[pH 8.4\], 50 mM KCl), 1.25 U Platinum Taq DNA polymerase (Invitrogen^®^; CA, USA), 0.4 mM dNTPs, 1.5 mM MgCl~2~, 0.4 μM of each primer; and 100 ng of DNA sample. The amplification cycles were started with an initial denaturation at 94°C for 3 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 60 s and elongation at 72°C for 2 min, followed by a final extension at 72°C for 7 min. The amplification products were visualized in a 2% agarose gel stained with ethidium bromide. DNA extracted from Daudi cells was used as a positive control of the reactions, and reaction mix without DNA was used as a negative control. For confirmation of the specificity of reaction, amplification products from the EBNA1 gene were cloned with TOPO TA Cloning Kit (Invitrogen^®^; CA, USA) and sequenced using the ABI PRISM^®^ BigDye Terminator v3.0 Cycle Sequencing Kit (Applied Biosystems^®^; CA, USA) and ABI Prism 3100 DNA Sequencer (Applied Biosystems^®^; CA, USA).

### Statistical Analysis

The analyses were carried out using the statistical programs EPINFO^®^ 6.04d and SPSS^®^ 17.0. The data were evaluated by the chi-square test or Fisher's exact test (2-sided). The results were considered statistically significant when p-values were less than 0.05. For the agreement analysis of the techniques, Cohen's kappa index was used and interpreted according to the classification of Landis and Koch ([@b29]). Considering the ISH as the gold standard method for EBV detection in tumor tissues, the sensitivity and specificity values were also calculated for PCR.

RESULTS\>
---------

The comparison of the clinico-pathological data and EBV detection by ISH and PCR is shown in the [Table 1](#table1){ref-type="table"}. No statistically significant differences were found between the EBV-associated gastric carcinomas from São Paulo and Ceará States with regard to epidemiological and pathological parameters, and therefore, they were analyzed as one group. Out of 192 cases, the PCR was performed in 151 and ISH in 160, while both techniques were performed in 120 cases. The percentage of positive cases by PCR was higher than by ISH. Seventy-three out of 151 (48.3%) cases submitted to the PCR technique were EBV-positive ([Figure 1](#fig1){ref-type="fig"}), while 11 out of 160 (6.9%) were ISH-positive, showing a strong nuclear staining ([Figure 2](#fig2){ref-type="fig"}). The majority (9 out of 11) of the ISH-positive cases exhibited a diffuse staining pattern. In one case with diffuse and one with focal staining pattern, EBV was also observed in lymphocytes. EBV was not observed in surrounding noncancerous or preneoplastic cells. All thirty cases submitted to in situ hybridization utilizing the GenPoint Detection System^®^ demonstrated the same results as with the standard technique: twenty-eight EBV-negative and two EBV-positive cases.

###### 

Correlation of the clinico-pathological findings with PCR and in situ hybridization data.

                                                      In situ Hybridization   PCR                                                            
  --------------------------------------------------- ----------------------- ----------- ------------ ------- ----- ----------- ----------- -------
  Total                                               160                     11 (6.9)    149 (93.1)           151   73 (48.3)   78 (51.7)   
  Sex                                                 118                                              0.162   109                           0.236
  Male                                                                        9 (90)      70 (64.8)                  39 (65)     37 (75.5)   
  Female                                                                      1 (10)      38 (35.2)                  21 (35)     12 (24.5)   
  Age distribution[\*](#tf1-1){ref-type="table-fn"}   117                                              0.795   108                           0.256
  15--44                                                                      1 (10)      10 (9.3)                   7 (11.7)    3 (6.3)     
  45--54                                                                      2 (20)      21 (19.6)                  7 (11.7)    12 (25)     
  55--64                                                                      1 (10)      25 (23.4)                  18 (30)     11 (22.9)   
  \> 65                                                                       6 (60)      51 (47.7)                  28 (46.6)   22 (45.8)   
  Anatomic localization                               157                                              0.432   126                           0.893
  Upper                                                                       3 (27.3)    23 (15.8)                  10 (17.5)   11 (15.9)   
  Intermediate                                                                3 (27.3)    29 (19.9)                  9 (15.8)    13 (18.8)   
  Lower                                                                       5 (45.4)    94 (64.3)                  38 (66.7)   45 (65.2)   
  Lauren's classification                             160                                              0.098   150                           0.745
  Intestinal                                                                  10 (90.9)   93 (62.4)                  49 (68.0)   55 (70.5)   
  Diffuse                                                                     1 (9.1)     56 (37.5)                  23 (31.9)   23 (29.4)   
  Tumor stage                                         160                                              0.533   150                           0.287
  In situ                                                                                                            1 (1.3)     0 (0)       
  IA                                                                          0 (0)       4 (2.7)                    3 (4.1)     3 (3.9)     
  IB                                                                          1 (9.1)     14 (9.4)                   3 (4.1)     10 (12.9)   
  II                                                                          1 (9.1)     32 (21.5)                  11 (15.1)   18 (23.4)   
  IIIA                                                                        2 (18.2)    41 (27.5)                  18 (24.7)   17 (22.1)   
  IIIB                                                                        4 (36.3)    23 (15.4)                  16 (21.9)   12 (15.6)   
  IV                                                                          3 (27.3)    35 (23.5)                  21 (28.8)   17 (22.1)   
  Tumor differentiation                               156                                              0.497   118                           0.663
  Undifferentiated                                                            0 (0)       1 (0.7)                    1 (1.9)     0 (0)       
  Poorly                                                                      3 (30)      58 (39.7)                  19 (35.2)   25 (39.1)   
  Moderately                                                                  7 (70)      70 (47.9)                  27 (50)     29 (45.3)   
  Well differentiated                                                         0 (0)       17 (11.6)                  7 (12.9)    10 (15.6)   

ISH(+) group age average = 61.2 ; PCR(+) group age average = 61.53

![Agarose gel electrophoresis of products from EBNA1 gene amplification (269 bp). 100bp = ladder; Lanes 1-11 = EBVpositive samples; C(+) = positive control; H2O = water; C(-) = negative control.](bjm-43-393-g001){#fig1}

![Detection of EBV by in situ hybridization. Strong nuclear staining was observed in gastric carcinoma cells (arrows).](bjm-43-393-g002){#fig2}

Although statistically significant differences were not found between the EBV(+) and EBV(-) tumors, by either technique, a predominance of EBV-positive cases was observed in males and in older individuals. The intestinal tumors were the most frequent subtype and the lower gastric region was the most frequent gastric localization associated with EBV. Nevertheless, the majority of the cases were in advanced stages, especially in the IIIB and IV, and in the moderately differentiated tumors. Despite these characteristics being found by both techniques, they were more evident by ISH, which is seen by the trend (p=0.09) for the intestinal-type tumors in the EBV-positive cases. However, the ISH-positive cases showed a slight increase in tumors localized in the upper and intermediate regions in comparison with ISH-negative cases.

The correlation between PCR and ISH is shown in the [Table 2](#table2){ref-type="table"}. Among the 120 investigated cases, there was agreement in 67 (55.8%), including (+/+) and (-/-) cases. Disagreement was observed in 53 (44.2%) cases. EBV was detected by both techniques only in 5 out of 120 cases (4.1%), while both methods showed negative results in 62 cases (51.6%). Nevertheless, 4 (3.3%) ISH-positive cases were PCR-negative, while 49 (40.8%) PCR-positive cases were ISH-negative. Cohen's kappa index was 0.034, whereas the PCR method demonstrated a sensitivity value of 55.5% and specificity value of 55.8%.

###### 

Correlation between the results of the PCR and in situ hybridization techniques.

            PCR        
  --------- ----- ---- -----
  EBV (+)   5     4    9
  EBV (-)   49    62   111
  Total     54    66   120

Cohen's kappa index: 0.034 (SE: 0.052); Sensibility: 55.5% Specificity: 55.8%

DISCUSSION
----------

Gastric cancer is the fourth most frequent neoplasm in the world and the second leading cause of death from cancer ([@b6], [@b41]). According to the Brazilian National Cancer Institute ([@b6]), gastric cancer is the fourth most common cancer among men and the sixth among women. Regarding the EBV association, in spite of consensus about some clinico-histopathological aspects of EBV-associated gastric carcinomas, there is still controversy in the literature on some points, given the complexity of this type of cancer. In this context, the present study contributes new data, considering the clinico-pathological features versus the EBV infection in cases from two Brazilian states that have a high incidence of gastric cancer. Nevertheless, few studies have used PCR for EBV detection, and most of them have used this technique as screening prior to the application of ISH due to the possibility of viral genome amplification from infected lymphocytes in the tumor stroma, as discussed by Trimeche et al. ([@b55]). In the present work, both techniques were independently performed and their results were compared.

The frequency of EBV-positive gastric carcinoma varies widely around the world, ranging from 0% to 23.6% ([Table 3](#table3){ref-type="table"}). In this study, the overall frequency of EBV by ISH (6.9%) is in agreement with the two other Brazilian studies, even considering that the two studied regions have different habits and socioeconomic conditions ([@b27], [@b33]). These frequencies were also similar to those found in Mexico (8.1%), France (8.5%), China (6.4% - 7%), Korea (5.6% - 7.3%), Russia (8.7%), Japan (5.2% - 6.7%) and USA (5.1%) (9, 14, 19, 21, 24, 26, 30, 34, 35, 38, 46, 52, 54, 56, 57). The highest EBV frequencies were found in the USA (16%), Germany (18%; 19.6%), Japan (19.3%), Korea (19.6%), and Chile (23.6%) (10, 15, 22, 25, 40, 47) and the lowest frequencies in Peru (3.9%), England (0%), United Kingdom (1.8%), New Guinea (1.3%), Iran (3.2%), Tunisia (4.1%) and Italy (4.6%) (1, 31, 36, 43, 49, 55, 59). The presence of both high and low frequencies in developed and developing countries indicates that economic conditions are not a relevant aspect for EBV-associated gastric carcinomas. On the other hand, the EBV detection by PCR (48.3%) demonstrated a frequency similar to that obtained by Nakamura et al. ([@b37]) (47%), but different from the results obtained by Leoncini et al. ([@b31]), Oda et al. ([@b38]) and Trimeche et al. ([@b55]), 6.1%, 21.6% and 36%, respectively. In general, all PCR frequencies were higher than ISH frequencies. In the present study, sequencing of the amplification products confirmed the specificity of PCR.

###### 

Summary of studies, clustered by world regions, which evaluate the association of the EBV with gastric carcinomas.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country                  Techniques                                 Freq.       \%                  Tumor type                        Cell type stained                              Reference   Year
  ------------------------ ------------------------------------------ ----------- ------------------- --------------------------------- ---------------------------------------------- ----------- ------
  USA                      PCR                                        1/1         100                 Lymphoepithelial type carcinoma   Tumor cells                                    7           1990

                           PCR                                        NR          \-                  carcinoma                         tumour cells                                   47          1992

                           ISH-DNA[\*](#tf3-1){ref-type="table-fn"}   22/138      16                                                    Dysplastic epithelium                                      

                           ISH-EBER1                                  22/138      16                                                                                                               

                           ISH-EBER1                                  11/95       12                  Carcinoma                         Tumor cells                                    18          1996

                                                                                                                                        Dysplastic epithelium                                      

                           ISH-EBER                                   12/235      5.1                 Carcinoma                         Tumor cells                                    56          2009

  Mexico                   ISH-EBER1                                  11/135      8.1                 Carcinoma                         Tumor cells                                    21          1999

  Brazil                   ISH-EBER1                                  24/300      8                   Carcinoma                         Tumor cells                                    27          2001

                           ISH-EBER1                                  6/53        11.3                Carcinoma                         Tumor cells                                    33          2004

  Colombia                 ISH-EBER1                                  23/178      13                  Carcinoma                         Tumor cells                                    8           2003

  Peru                     ISH-EBER1                                  10/254      3.9                 Carcinoma                         Tumor cells                                    59          2005

  Chile                    ISH-EBER1                                  22/93       23.6                Carcinoma (only cardia tumors)    Tumor cells                                    10          2005

  UK                       ISH-EBER1                                  3/168       1.8                 Carcinoma                         Tumor cells                                    43          1993

  England                  ISH-EBER1                                  0/17        0                   Carcinoma                         \-                                             49          1994

  France                   ISH-EBER1                                  5/59        8.5                 Carcinoma                         Tumor cells                                                

  Surrouding lymphocytes   46                                         1996                                                                                                                         

  Germany                  ISH-EBER1                                  7/39        18                  Carcinoma                         Tumor cells                                    40          1994

                           ISH-EBER                                   18/92       19.5                Carcinoma                         Tumor cells                                    15          2011

  Italy                    PCR                                        4/65        6.1                 Carcinoma                         Tumor cells                                    31          1993

  ISH-EBER1                3/65                                       4.6                                                                                                                          

  Japan                    ISH-EBER1                                  120/1795    6.7                 Carcinoma                         Tumor cells                                    54          1993

                                                                                                                                        Surrouding lymphocytes                                     

                           PCR                                        NR                              Carcinoma                         Tumor cells                                    13          1994

  ISH-EBER1                8/72                                       11                              Surrouding lymphocytes                                                                       

                                                                                                                                        Non-neoplastic epithelium                                  

                           PCR                                        46/99       47                  Carcinoma                         Tumor cells                                    37          1994

                           ISH-EBER1                                  4/42        9.5                                                                                                              

                           ISH-EBER1                                  33/513      6.4                 Carcinoma                         Tumor cells                                    52          1999

  Surrouding lymphocytes                                                                                                                                                                           

                           ISH-EBER1                                  23/119      19.3                Carcinoma                         Tumor cells                                    22          2001

  9.5                      Carcinoma                                                                                                                                                               

                           Tumor cells                                37          1994                                                                                                             

  Surrouding lymphocytes                                                                                                                                                                           

                           PCR                                        21/97       21.6                Carcinoma                         Tumor cells                                    38          2003

                           ISH-EBER1                                  5/97        5.2                                                   Surrouding lymphocytes                                     

                           ISH-EBER1                                  28/417      6.7                 Carcinoma                         Tumor cells                                    24          2003

  China                    ISH-EBER1                                  7/74        9.5                 Carcinoma                         Tumor cells\                                               
                                                                                                                                        Dysplastic epithelium\                                     
                                                                                                                                        Surrouding lymphocytes                                     

                           ISH-EBER1                                  13/185      7                   Carcinoma                         Tumor cells                                    57          2004

                           ISH-EBER1                                  11/172      6.4                 Carcinoma                         Tumor cells                                    34          2005

                           13/185                                     \-          7.03                Carcinoma                         Tumor cells                                    35          2006

  60                       1994                                                   PCR-Southern blot   ISH-EBER1                         NR                                                         

                           ISH-EBER1                                  45/676      6.7                 Carcinoma                         Tumor cells                                    19          2010

  Thailand                 PCR                                        ISH-EBER1   NR                  6/55                              \-                                                         

                           11                                         Carcinoma   Tumor cells         Dysplastic epithelium             20                                             1995        

  Korea                    ISH-EBER1                                  12/89       13.5                Carcinoma                         Tumor cells                                    48          1996

                           ISH-EBER1                                  17/306      5.6                 Carcinoma                         Tumor cells                                                

                                                                                                                                        Surrouding lymphocytes                         9           2001

                           ISH-EBER1                                  63/1127     5.6                 Carcinoma                         Tumor cells                                    30          2004

                           ISH-EBER                                   23/117      19.6                Carcinoma                         Tumor cells                                    25          2010

                           ISH-EBER                                   18/247      7.3                 Carcinoma                         Tumor cells                                    26          2010

  Russia                   ISH-EBER1                                  18/206      8.7                 Carcinoma                         Tumor cells                                    14          1997

  Malaysia                 ISH-EBER1                                  5/50        10                  Carcinoma                         Tumor cells                                    23          2003

  New Guinea               ISH-EBER1                                  2/150       1.3                 Carcinoma                         Tumor cells                                    36          2004

  Kazakhstan               ISH-EBER1                                  14/139      10.1                Carcinoma                         Tumor cells                                    2           2005

  Tunisia                  ISH-EBER                                   35/96       4/96                36.4                                                                                         

                                                                                  4.1                 Carcinoma                         Tumor cells                                                

                                                                                                                                        Non-neoplastic hyperplastic epithelial cells   55          2009

  Iran                     ISH-EBER1                                  9/273       3.2                 Carcinoma                         Tumor cells                                    1           2007
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ISH targeted to the viral DNA NR, not reported

The predominance of EBV-positive cases in males and in advanced ages was observed by both techniques (PCR and ISH) and reproduced the findings obtained by many authors around the world using the ISH technique ([@b2], [@b8], [@b15], [@b19], [@b22], [@b25], [@b26], [@b28], [@b30], [@b20], [@b21], [@b22]). No clinico-pathological data were found related to EBV detection by PCR in the literature.

Unlike the data for PCR detection, the data for the ISH-positive cases showed somewhat more frequent localization in the upper and intermediate gastric regions compared to the ISH-negative cases and displayed a strong trend for the intestinal type. These findings agree with other studies that point to the cardia and corpus as the gastric regions more associated with EBV-ISH-positive cases ([@b13], [@b14], [@b19], [@b25], [@b28], [@b39], [@b54], [@b55], [@b59]). However, the correlation with Lauren's classification is still controversial. In this scenario, the present finding corroborates the findings of some authors, indicating the intestinal type as being more associated with EBV-positive gastric carcinomas ([@b20], [@b60], [@b61]), but others indicate the diffuse type ([@b2], [@b19], [@b25], [@b28], [@b38]) or similar frequencies between the two histological types ([@b8], [@b47], [@b55]). Nevertheless, Kijima et al. ([@b24]) reported that individuals with intestinal-type EBV-ISH-positive carcinomas have a worse prognosis than with the diffuse type, which corroborates the observed predominance of EBV-ISH-positive cases in advanced tumor stages (IIIB and IV). Although no significance was found related to the presence of the EBV in moderately or poorly differentiated tumors, by either technique, it is in agreement with the few papers found in the literature ([@b14], [@b31], [@b52], [@b56], [@b59]).

The comparison of the results from the two techniques employed showed no concordance as indicated by Cohen's kappa index (κ=0.034), which according to Landis and Koch ([@b29]) represents a slight agreement. Furthermore, the sensitivity and specificity values for PCR did not show satisfactory values, i.e., 55.5% and 55.8%, respectively. In this context, Gulley ([@b17]) attributes the elevated frequency of EBV-positive cases detected by PCR to the amplification of viral DNA from surrounding infected lymphocytes, not from tumor cells, explaining the low specificity value. However, among the 160 cases evaluated by ISH, only two displayed infected lymphocytes, with both of them also exhibiting stained tumor cells and one even being PCR-negative. To verify whether the low frequency of ISH-positive lymphocytes was due to the small quantity of circulating infected lymphocytes, complementary tumor specimens (other paraffin blocks) were obtained from four random PCR-positive cases and likewise submitted to ISH, but like the first results with the main specimens, no infected lymphocytes were observed. Another hypothesis refers to a possible reduced EBER1 expression in tumor cells or lymphocytes to undetectable levels due to RNA degradation during histological procedures as suggested by Gulley ([@b17]); however, the employment of a more sensitive ISH method by GenPoint^®^ confirmed the ISH negativity in the twenty-eight samples tested. This technique employs tyramide amplification reagents and assures the potential detection of single-copy nucleic acid ([@b11], [@b32]).

Regarding this point, our findings raise the following query: How do we account for the high EBV frequency by PCR, in view of the low number of infiltrating infected lymphocytes in the tumor tissue? In this context, Oda et al. ([@b38]) evaluated cases with EBV-negative tumor cells by ISH, and found 14 PCR-negative cases with the presence of infected lymphocytes detected by ISH and 10 PCR-positive cases with no evidence of infected lymphocytes. These findings suggest that the PCR results, at least in part, were not related to the presence of infected lymphocytes. Meanwhile, Ryan et al. ([@b45]), using quantitative-PCR to estimate EBV load in gastric carcinomas by the analysis of five viral regions and comparing the findings with the standard ISH results, established thresholds to define what is EBV detection in tumor cells, in surrounding lymphocytes or in non-neoplastic epithelium, with the highest viral loads in the cases exhibiting ISH-positive tumor cells. Additionally, the above-mentioned work shows two important findings that can help us resolve some uncertainties encountered. First, the verification of polymorphisms in the EBV genome, which impaired the amplification of some viral genes in a few cases, could explain the PCR-negative cases with ISH-positivity in tumor cells and lymphocytes. Second, the presence of cases with low viral loads associated with ISH-negativity for both tumor cells and lymphocytes, attributed by the authors to the presence of EBV in non-neoplastic gastric epithelium, could explain the PCR-positive cases with no evidence of ISH-positivity. This first consideration could also explain the low sensitivity value of PCR in relation to the ISH method.

Nevertheless, some studies have demonstrated, using the ISH method with the EBER1 probe, the presence of EBV in dysplastic tissue, and even in non-tumor tissue surrounding the tumor (13, 18, 20, 47, 55, 60). However, this is a controversial issue. Curiously, Yanai et al. ([@b58]) demonstrated the presence of EBV in dysplastic tissue in two cases of chronic atrophic gastritis with the ISH method targeting the viral genome. Considering these data, it is possible that the non-tumor gastric epithelium may be a reservoir for EBV, as suggested by Takada ([@b51]), showing a different behavior at this site. One hypothesis could be a latency pattern different from that usually observed in tumor cells, characterized by the absence of EBER1 expression. This condition corroborates the explanation for DNA amplification and the ISH-negativity in tumor cells and/or surrounding lymphocytes, as well as the results of Yanai et al. ([@b58]).

Although EBERs are expressed in four known latency patterns, some authors have already reported the absence of these viral RNAs in some EBV-associated tumors such as hepatocellular carcinomas ([@b50]) and breast carcinomas ([@b5], [@b16]). Therefore, in order to elucidate this issue, it would be better to use a more sensitive in situ hybridization method, such as the GenPoint system, with the probe targeting a conserved region of EBV DNA, preferentially the BamH1W sequence, because this is a repetitive region that shows approximately 10 copies per EBV genome ([@b44]).

Among the four ISH-positive/PCR-negative cases, two demonstrated a focal staining pattern by ISH, initially suggesting that the specimens subjected to PCR had no EBV genome. On the other hand, the two remaining cases exhibited a diffuse staining pattern, suggesting one of the following explanations: (a) experiment failure; (b) DNA degradation; (c) the absence of EBV in some parts of the tumor; or (d) presence of polymorphisms in the sequences of the viral genome amplified. Notably, the experiments were repeated and the initial results were corroborated. DNA preservation was also confirmed by amplification of different genes in other on-going studies in our laboratory. Considering that focal staining by ISH was observed in two cases, it is possible that the virus was not present in the whole tumor; maybe the infection had occurred after tumor transformation or the EBV had trigged the "hit and run mechanism" after tumor establishment, as proposed by Ambinder ([@b3]). However, it looks more probable that the PCR negativity in these four cases were due to polymorphisms in the viral genome resulting in false-negatives, as verified by Ryan *et al*. ([@b45]).

CONCLUSIONS
-----------

In summary, there was no concordance between the two techniques, PCR using primers for the EBNA1 gene and ISH for EBER1 detection. Considering that this disagreement was not due to DNA or RNA degradation, we believe that the existence of another latency pattern, characterized by the absence of EBER1 expression, as well as the possibility that EBV in some cases is not present in the whole tumor or that there are polymorphisms in the sequences of the viral genome amplified by the primers used, could explain the observed discrepancy. However, different approaches are needed to confirm this hypothesis and the importance of EBV detection by PCR for elucidating tumor pathology. Moreover, in this study EBV-positive gastric carcinomas were characterized by their association with males, older patients, lower gastric region, intestinal type, advanced stage and poorly to moderately differentiated tumors.
